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Background: Older people are a growing population. They live longer, but often have multiple chronic diseases. As
a consequence, they are taking many different kind of medicines, while their vulnerability to pharmaceutical
products is increased. The objective of this study is to describe the medicine utilization pattern in people aged
65 years and older in Belgium, and to estimate the prevalence and the determinants of excessive polypharmacy.
Methods: Data were used from the Belgian Health Interview Survey carried out in 2008. Each respondent was
asked to show to the interviewer all medicines that he/she had taken in the 24 h prior to the interview. Excessive
polypharmacy was defined as the use of nine different kind of medicines or more in the past 24 h; the relation
with the Region of residence, age, gender and additional factors, such as socioeconomic status, living situation,
health status and contacts with health services, was explored through multivariate models.
Results: Eight percent of the older people (65 years or more) belong to the excessive polypharmacy group. Factors
most strongly associated with excessive polypharmacy are: having a longstanding illness, chronic condition or
handicap, at least 1 contact with a general practitioner in past 2 months and self-reported depression during the
last year. Ninety percent of persons in the excessive polypharmacy group are taking medicines active on the
cardiovascular system.
Conclusions: In order to optimize the use of medicines, it is necessary to find a balance between adequate
treatment of diseases and avoiding adverse effects of medicines. Interventions should aim to increase awareness
among healthcare professionals and patients; they should focus on general practitioners and patients with
cardiovascular diseases, those suffering from depression and those aged 80 years and over. Monitoring excessive
polypharmacy in the older population remains important. Further studies should explore more in depth other and
more specific determinants of excessive polypharmacy.
Keywords: Polypharmacy, Multiple medication/medicine/drug use, Elderly, Aged, General population, Health
interview survey, BelgiumBackground
Older people are a growing population. They live longer,
but often have multiple chronic diseases and take many
different kind of medicines, while their vulnerability to
pharmaceutical products is increased. There is also an
increase in the availability of medicines on the market
and, due to the development of generic products, an eas-
ier access to medicines.
There is no consensus in the literature on the defin-
ition of the concept of polypharmacy and excessive* Correspondence: johan.vanderheyden@wiv-isp.be
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(http://creativecommons.org/publicdomain/zepolypharmacy. Polypharmacy can for instance either be
defined by a single count of medicines - frequently five
or more medicines used concomitantly [1], or by the
consumption of more medicines than clinically indicated
or by the consumption of medicines that are not clinic-
ally indicated [2]. The WHO defines polypharmacy as
“the administration of many drugs at the same time or
the administration of an excessive number of drugs” [3].
Excessive polypharmacy (EPP) is defined as the con-
comitant use of nine/ten or more medicines taken regu-
larly or as-needed [4–12].
The way in which the medicine use is measured
varies also from one study to the other: it can involvecle is distributed under the terms of the Creative Commons Attribution 4.0
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vaccines, magistral preparations, herbal preparations,
vitamins, minerals, dietary supplements, alternative
medicines (homeopathic medicines). They can be
taken on a regular basis and “as-needed”, one-time-
only, for systemic or local use.
There are several risks associated with medicine use,
such as adverse effects, medicine-medicine and medicine-
disease interactions, decreasing adherence to medicine
therapy or errors in the actual use of the medicines. This
leads also to unnecessary health costs, related to medi-
cines “prescribing cascade”, medical consultations and
hospitalizations.
It is consequently important to monitor excessive
polypharmacy in the population and explore determi-
nants that contribute to it. In Europe, some studies
already explored this, but most of them consider only
home care patients [4] or nursing home patients [8, 10]
or are limited to a specific region [12, 13]. The present
study explores within a representative sample of the gen-
eral population in Belgium, the actual use of medicines
in people aged sixty-five years and older, taking into ac-
count socio-demographic information, health related in-
formation and health care consumption.
Methods
Study population
Data were used from the Belgian Health Interview Survey
carried out in 2008. Information was collected through a
face-to-face interview and a self-completion questionnaire
from a sample of 11,254 individuals, which is representa-
tive of the population living in Belgium. A stratified, clus-
tered multistage sampling design was implemented for
this survey [14]. The analyses for the current study were
restricted to the population of 65 years and older (N =
2835) with both community-based and institutionalized
persons included.
Definition
Extensive information was gathered on the use of medi-
cines. Each respondent was asked to show to the inter-
viewer all medicines that he/she had taken in the 24 h
prior to the interview. The brand name and the national
identification code (unique code for each registered
medicine in Belgium) was recorded by the interviewer
and subsequently coded with the Anatomical Therapeutic
Chemical (ATC) classification system of the World Health
Organization (version 10 December 20091). Drug groups
were taken into account until the 5th level of the ATC
classification. A combination medicine (multiple compo-
nent products) was considered as a single medicine. The
dosage was not taken into account. Medicines with differ-
ent brand names and generics having the same ATC-code
were considered as one medicine.The study considered medicines taken in the 24 h
prior to the interview, including both those taken on a
regular basis and those taken “as needed”. It was limited
to official medicines that were used in an ambulatory
setting, for systemic or local use, and listed in the
Annotated Directory of Medicines published by the
Belgian Centre for Pharmacotherapeutic Information
(BCPI; [15]). They could be prescribed or OTC medi-
cines. Excessive polypharmacy was defined here as the
use of nine different medicinal products or more in
the past 24 h.
Statistical analysis
The use of medicines was explored in relation to poten-
tial determinants according to the literature. Apart from
Region of residence, age and gender, several socioeco-
nomic variables were considered, such as educational at-
tainment (defined at the level of the household),
equivalent household income, living or not in an institu-
tion for elderly, health status (longstanding illnesses,
chronic conditions or handicaps, depression that has
lasted for at least 2 weeks during the past 12 months),
contacts in the past 2 months either with a general prac-
titioner (GP) or with a specialist, and hospitalization in
the past 12 months.
In a first step a univariate analysis was conducted to
describe the polypharmacy level in the study sample;
three groups were considered: non polypharmacy (0–4
medicines), polypharmacy (5–8 medicines) and EPP (at
least 9 medicines). In a second step, the relation between
polypharmacy and its determinants, but also between
polypharmacy and the use of specific group of medicines
was explored in the bivariate analyses. Differences in the
bivariate analyses were assessed with Chi-square tests.
Multivariate analyses were used to assess the associ-
ation between specific groups of medicines and potential
determinants. Determinants of polypharmacy were ex-
plored in a multinomial logistic regression model.
Statistical analyses were performed with SAS®9.3, tak-
ing into account the sampling design of the survey.
Results
The mean number of medicines used per person aged
65 years and over is 3.5 (range: 0–19). Almost one fifth
of the population (18.1 %; 95 % CI: 15.8–20.4) did
not take any medicine during the past 24 h, 48.9 %
(95 % CI: 46.1–51.7) took 1 to 4 medicines; 24.8 %
(95 % CI: 22.4–27.1) belongs to the polypharmacy
group (Table 1) and 8.2 % (95 % CI: 6.3–10.1) to the
excessive polypharmacy group. When we consider
only persons living in an institution for elderly (N = 313),
the mean number of medicines used per person is 4.5
(range: 0–18) and the percentage in the excessive poly-
pharmacy group reaches 16.8 % (95 % CI: 11.2–22.3). For
Table 1 Characteristics of the population of 65 years and older, in percentage, Belgium, 2008
Characteristic Total mean: 3.5 0–4 medicines
(N = 1769) mean: 1.7
5-8 medicines
(N = 811) mean: 6.1
> = 9 medicines
[9–19] (N = 255) mean: 10.6
% 95 % CI % 95 % CI % 95 % CI % 95 % CI
N = 2835 100.0 67.0 64.4–69.7 24.8 22.4–27.1 8.2 6.3–10.1
Demographics (N = 2835)
Gender
Males 41.2 39.1–43.3 43.5 40.7–46.3 37.6 32.9–42.3 33.4 19.3–47.5
Females 58.8 56.7–60.9 56.5 53.7–59.3 62.4 57.7–67.0 66.6 52.5–80.7
Age
65–69 23.2 20.5–25.9 26.8 23.3–30.2 17.2 13.0–21.4 12.2 5.5–18.9
70–74 27.2 24.1–30.3 27.9 24.3–31.5 24.8 19.5–30.0 28.7 13.4–44.0
75–79 19.4 17.1–21.7 19.4 16.5–22.3 20.0 16.1–24.0 17.1 10.1–24.1
> = 80 30.2 27.7–32.8 25.9 23.0–28.9 38.0 33.1–42.8 42.0 31.1–52.9
Socioeconomic status
Education (N = 2689)
No degree/Primary 30.4 27.3–33.4 27.6 24.1–31.1 35.0 29.9–40.0 38.9 27.4–50.4
Lower secondary 24.4 21.0–27.7 22.4 18.8–26.0 26.3 21.1–31.4 34.9 20.1–49.8
Higher secondary 27.0 23.8–30.2 29.2 25.3–33.1 23.9 19.1–28.8 18.4 10.3–26.5
Higher education 18.2 15.6–20.9 20.8 17.5–24.0 14.8 10.6–19.0 7.8 3.2–12.3
Equivalent household income (N = 2271)
Quintile 1 20.5 17.2–23.8 19.6 16.2–23.0 17.6 13.6–21.6 37.1 20.7–53.6
Quintile 2 32.8 29.2–36.4 32.5 28.2–36.9 34.0 28.4–29.6 31.0 19.8–42.3
Quintile 3 25.4 21.9–28.8 24.2 20.1–28.3 30.2 24.5–35.8 20.3 11.1–29.5
Quintile 4 11.2 9.1–13.4 11.7 9.0–14.4 10.6 7.2–14.0 9.0 3.7–14.4
Quintile 5 10.1 7.9–12.2 11.9 9.2–14.7 7.6 4.2–11.0 2.5 0.2–4.8
Living situation (N = 2820)
Living alone or with other person(s) in home setting 94.4 93.4–95.4 95.9 94.8–96.9 92.3 90.3–94.4 88.6 84.0–93.2
Living in a residential home for the elderly 5.6 4.6–6.6 4.1 3.1–5.2 7.6 5.6–9.7 11.4 6.8–16.0
Region (N = 2835)
Flemish Region 61.2 58.9–63.4 66.2 63.4–68.9 50.8 45.8–55.8 51.8 39.8–63.9
Brussels Region 8.8 8.1–9.5 8.5 7.6–9.5 9.7 8.0–11.4 7.8 4.6–10.9
Walloon Region 30.1 28.0–32.1 25.3 22.7–27.9 39.5 34.7–44.3 40.4 29.6–51.1
Health status
Longstanding illness, chronic conditions or
handicaps (N = 2819)
Yes 54.0 51.0–56.9 42.3 38.7–45.9 73.4 69.0–77.9 90.2 85.0–95.4
No 46.0 43.1–49.0 57.7 54.1–61.3 26.6 22.1–31.0 9.8 4.6–15.0
Depression during the past 12 months (N = 2794)
Yes 6.8 4.9–8.6 4.2 2.8–5.5 8.0 5.6–10.4 24.4 8.9–39.9
No 93.2 91.4–95.1 95.8 94.4–97.2 92.0 89.6–94.4 75.6 60.1–91.1
Contact with health services
Contact with GP in past 2 months (N = 2811)
Yes 73.8 71.1–76.4 65.4 61.8–69.0 89.4 86.4–92.5 94.1 89.9–98.3
No 26.2 23.6–28.9 34.6 31.0–38.2 10.6 7.4–13.6 5.9 1.7–10.1
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Table 1 Characteristics of the population of 65 years and older, in percentage, Belgium, 2008 (Continued)
Contact with specialist in past 2 months (N = 2817)
Yes 27.8 25.3–30.3 24.8 21.6–27.9 33.3 28.2–38.4 36.3 25.6–47.0
No 72.2 69.7–74.7 75.2 72.1–78.3 66.7 61.6–71.8 63.7 53.0–74.4
Inpatient hospitalization in past 12 months (N = 2813)
Yes 18.2 16.0–20.4 14.0 11.5–16.5 23.5 19.4–27.6 36.1 25.1–47.1
No 81.8 79.6–84.0 86.0 83.5–88.5 76.5 72.4–90.6 63.9 52.9–74.9
1 day patient hospitalization in past 12 months (N = 2807)
Yes 11.0 9.1–12.9 10.2 7.9–12.6 13.4 9.5–17.4 10.3 5.0–15.5
No 89.0 87.1–90.9 89.8 87.4–92.1 86.6 82.6–90.5 89.7 84.5–95.0
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are respectively 3.5 (range 0–19) and 7.7 % (95 % CI:
5.7–9.8).
Description of the study population by level of
polypharmacy
Socio-demographic characteristics
The mean age of the study population is 75.5 years
(range: 65–105). There are 58.8 % of women in the study
group (Table 1).
The age distributions are significantly different between
the “non-polypharmacy” group and the polypharmacy
groups, but not between the two polypharmacy groups.
In the EPP-group, only 7.8 % has a higher education
and 2.5 % has a higher household income, versus 14.8
and 7.6 % respectively in the polypharmacy group, and
20.8 and 11.9 % respectively in the “non-polypharmacy”
group.
In the two polypharmacy groups, the percentage of
persons living in a residential home for the elderly (re-
spectively 7.6 % in the polypharmacy group and 11.4 %
in the EPP-group) is higher than in the “non-polyphar-
macy” group (4.1 %), but there is no significant difference
between the two polypharmacy groups. The same is ob-
served when only the persons aged 80 and older are con-
sidered with respectively 18.3 % (95 % CI: 13.6–23.0) and
21.1 % (95 % CI: 13.5–28.7) institutionalized people in the
polypharmacy and EPP-groups versus 11.8 % (95 % CI:
8.8–14.9) in the non-polypharmacy group.
In the two polypharmacy groups, the percentage of
persons living in the Flanders Region is lower than in
the “non-polypharmacy” group (and the opposite is ob-
served for the persons living in the Wallonia Region),
but there is no difference between the two polypharmacy
groups.
Health status and use of health care characteristics
Suffering from a longstanding illness, chronic condition
or handicap is associated with (excessive) polypharmacy
(Table 1); in addition there is a difference between the
polypharmacy (73.4 % of users) and the EPP (90.2 % ofusers) groups. 24.4 % of persons in the EPP-group were
suffering from depression in past 12 months versus 8.0
and 4.2 % respectively in the polypharmacy and “non-
polypharmacy” groups.
Recent contacts with health professionals are associ-
ated with (excessive) polypharmacy: 94.1 % of persons in
the EPP-group had a contact with a GP in the last two
months and 36.3 % with a specialist (versus respectively
65.4 and 24.8 % in the “non-polypharmacy” group), but
there is no difference between the two polypharmacy
groups.
At least one inpatient hospitalization in past 12 months
is associated with (excessive) polypharmacy (with in
addition a difference between the polypharmacy and the
EPP groups), while at least one day patient hospitalization
in past 12 months is not associated with (excessive)
polypharmacy.Use of specific groups of medicines by level of
polypharmacy
Table 2 presents the percentage of the population that
used medicines from a particular anatomical group (first
level of the ATC classification) for groups of medicines
used by at least 10 % of the persons: medicines active on
the cardiovascular system are the most frequently used
drugs, followed by the drugs acting on the nervous sys-
tem. The percentages of use of the groups vary accord-
ing to polypharmacy status but the ranking is the same.
Except for cardiovascular medicines, there is also a dif-
ference between the polypharmacy group and the EPP
group. Among people in the polypharmacy groups, more
than 90 % use cardiovascular medicines. The use of
medicines acting on the nervous system occurs among
86.5 % of the people in the EPP group and 65.9 % of
those in the polypharmacy group.
Table 3 presents the percentage of the population that
used medicines from a particular pharmacological class
(ATC_3) by level of polypharmacy for the ten most fre-
quently used pharmacological subgroups. Antithrombotic
agents are the most commonly used pharmacological
Table 2 Percentage of population (65 years and older) using medicines, in function of the anatomical groupsa (ATC_1), according to
polypharmacy status (N = 2835), Belgium, 2008
ATC_1 Total 0–4 medicines (N = 1769) 5–8 medicines (N = 811) > = 9 medicines (N = 255)
% 95 % CI % 95 % CI % 95 % CI % 95 % CI
C Cardiovascular system 61.9 59.1–64.7 46.6 43.1–50.2 92.2 89.5–94.9 95.3 91.7–98.8
N Nervous system 37.6 34.7–40.6 21.2 18.3–24.0 65.9 61.0–70.7 86.5 79.6–93.3
A Alimentary tract and metabolism 33.5 30.7–36.4 18.3 15.5–21.2 56.5 51.3–61.7 88.0 82.7–93.3
B Blood and blood forming organs 31.2 28.5–34.0 17.2 14.5–19.9 54.9 49.8–59.9 74.3 65.7–82.9
M Musculo-skeletal system 18.1 15.7–20.5 11.5 9.0–14.0 25.2 20.7–29.7 50.6 38.5–62.7
R Respiratory system 12.1 9.9–14.3 5.1 3.5–6.6 20.8 16.1–25.5 42.9 29.6–56.2
afor those used by at least 10 % of the persons
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people with EPP.
Determinants for the use of specific groups of medicines
Factors associated with the use of medicines may differ
according to the type of medicine. Insight in this will
help to understand better the association between those
factors and polypharmacy. Therefore a multivariate ana-
lysis was performed considering drug groups at ATC_1
level (Table 4). Factors which are most associated with
the use of all drug groups are having a longstanding ill-
ness, chronic conditions or handicaps, and having had at
least one contact with a GP in past two months. A low
education is associated with a higher use of drugs acting
on the nervous system. For four of the six drug groups,
a higher consumption is observed in the Walloon Region
than in the other Regions.
People living in institutions for older people use less
cardiovascular medicines than those living at home (OR:
0.48). An analysis performed at ATC_2 level shows that
three groups of medicines active on the cardiovascular
system are significantly less frequently used inTable 3 Percentage of population (65 years and older) using medic
to polypharmacy status (N = 2835), Belgium, 2008
ATC_3 Tota
%
B01A Antithrombotic agents 30.5
C10A Lipid modifying agents, plain 27.9
C07A Beta blocking agents 24.2
A02B Drugs for peptic ulcer and gastro–oesophageal reflux disease 14.9
N05B Anxiolytics 13.4
C08C Selective calcium channel blockers with mainly vascular effects 12.7
C09A Ace inhibitors, plain 11.4
N06A Antidepressants 10.9
M01A Antiinflammatory and antirheumatic products, non-steroids 10.3
N05C Hypnotics and sedatives 10.2
afor the ten most frequently used pharmacological classesinstitutions: lipid modifying agents, beta blockers and
agents acting on the renin-angiotensin system.
Determinants of polypharmacy
The multinomial logistic regression shows that the
socio-demographic factors which are most associated
with EPP are as follows (Table 5): living in the Walloon
Region (OR: 2.57) and being aged ≥80 years (OR: 2.08);
they are associated to a lesser extent to polypharmacy.
Having no degree or a primary education is more associ-
ated with polypharmacy (OR: 1.52; 95 % CI: 1.07–2.15)
than with EPP (OR: 1.32; 95 % CI: 0.75–2.31).
For EPP-users, the highest odds ratio is found for the
group having the lowest equivalent household income,
but differences are statistically not significant and the
confidence intervals are very wide; no conclusion should
be drawn.
The analysis shows that the health related factors
which are most associated with EPP are as follows : hav-
ing a longstanding illness, chronic conditions or handi-
caps, at least one contact with a GP in past two months,
a self-reported depression during the last year. Thoseines, in function of pharmacological classesa (ATC_3), according
l 0-4 medicines (N = 1769) 5-8 medicines
(N = 811)
> = 9 medicines
(N = 255)
95 % CI % 95 % CI % 95 % CI % 95 % CI
27,8–33,3 17.0 14.2–19.7 53.3 48.2–58.4 72.5 63.6–81.4
25,0–30,7 18.7 15.8–21.7 44.8 39.7–50.0 51.3 39.3–63.3
21,4–26,9 13.7 11.3–16.1 42.2 37.2–47.2 55.2 43.6–66.7
12,6–17,1 6.2 4.5–8.0 25.7 21.1–30.4 52.4 40.5–64.2
11,3–15,6 6.1 4.5–7.6 22.0 17.7–26.4 47.4 34.9–59.9
10,4–15,0 6.8 4.8–8.8 21.5 16.9–26.1 34.0 19.7–48.4
9,6–13,2 6.2 4.2–8.2 21.8 17.6–25.9 22.0 14.5–29.6
9,2–12,5 3.3 2.2–4.3 23.2 18.6–27.9 35.5 25.1–45.8
8,2–12,4 6.7 4.9–8.5 13.5 9.7–17.2 29.8 14.9–44.8
8,4–12,0 5.4 3.6–7.3 18.1 14.0–22.1 24.8 16.1–33.5
Table 4 Determinants of use of specific categories of drugs - logistic regression (N = 2119)b, Belgium, 2008
Characteristic (reference category) ATC C (N = 1387) ATC N (N = 886) ATC A (N = 734) ATC B (N = 752) ATC R (N = 245) ATC M (N = 379)
OR 95 % CI OR 95 % CI OR 95 % CI OR 95 % CI OR 95 % CI OR 95 % CI
Gender (male)
Female 1.12 0.92–1.37 1.92b 1.58–2.34 1.44 1.18–1.76 0.61b 0.51–0.75 0.67b 0.50–0.90 1.18 0.93–1.50
Age (65–69)
70–74 1.05 0.76–1.46 1.50b 1.06–2.11 1.15 0.82–1.61 1.50b 1.06–2.13 0.82 0.49–1.38 1.01 0.68–1.48
75–79 1.67b 1.20–2.34 1.32 0.93–1.88 0.96 0.67–1.35 1.80b 1.27–2.56 0.86 0.52–1.42 1.01 0.68–1.49
> = 80 1.45b 1.10–1.90 1.81b 1.35–2.42 1.05 0.79–1.40 2.36b 1.75–3.19 0.89 0.59–1.35 0.82 0.59–1.14
Education (Higher education)
No degree/Primary 1.25 0.91–1.71 1.46b 1.07–1.98 1.17 0.86–1.58 1.33 0.98–1.81 1.23 0.78–1.93 1.25 0.87–1.79
Lower secondary 0.87 0.63–1.19 1.52b 1.12–2.08 0.92 0.67–1.26 1.16 0.85–1.59 1.22 0.77–1.95 1.36 0.95–1.96
Higher secondary 0.94 0.69–1.27 1.23 0.91–1.66 1.08 0.80–1.46 1.11 0.82–1.51 1.02 0.64–1.63 1.21 0.84–1.74
Equivalent household income (Quintile 5)
Quintile 1 0.95 0.65–1.38 1.12 0.77–1.63 1.20 0.82–1.75 0.91 0.63–1.32 1.00 0.56–1.77 0.93 0.59–1.44
Quintile 2 1.13 0.79–1.61 1.01 0.71–1.43 1.18 0.82–1.70 1.03 0.73–1.47 1.37 0.80–2.34 1.04 0.68–1.58
Quintile 3 1.37 0.95–1.96 1.18 0.83–1.70 1.12 0.77–1.62 1.07 0.75–1.54 1.24 0.71–2.16 1.08 0.70–1.67
Quintile 4 0.98 0.66–1.46 1.18 0.79–1.75 1.04 0.69–1.55 1.09 0.73–1.62 1.09 0.59–2.02 1.10 0.68–1.77
Living situation (Living at home)
Living in a residential home for
the elderly
0.48b 0.33–0.71 1.25 0.84–1.86 1.40 0.96–2.04 0.74 0.50–1.10 1.15 0.69–1.42 0.64 0.37–1.11
Region (Flemish Region)
Brussels Region 0.85 0.67–1.08 1.26 0.98–1.62 1.07 0.84–1.38 1.03 0.80–1.32 0.98 0.68–1.42 1.29 0.96–1.73
Walloon Region 1.76b 1.40–2.21 1.55b 1.25–1.93 1.51b 1.22–1.88 1.27b 1.02–1.57 0.99 0.72–1.37 1.23 0.95–1.61
Depression < 12 months (no)
Yes 0.77 0.52–1.13 4.76b 2.97–7.64 1.51b 1.06–2.17 0.77 0.52–1.14 1.55 0.97–2.48 0.70 0.43–1.16
Longstanding disease, condition or
handicap (no)
Yes 1.42b 1.16–1.73 1.90b 1.56–2.39 2.18b 1.78–2.67 1.65b 1.35–2.02 2.74b 1.96–3.83 1.66b 1.30–2.14
Contact with GP in past 2 months (no)
Yes 2.90b 2.31–3.66 1.86b 1.45–2.39 1.51b 1.17–1.96 1.86b 1.43–2.40 2.45b 1.54–3.90 1.18 0.87–1.60
Ambulatory contact with specialist in
past 2 months (no)
Yes 1.14 0.91–1.44 1.07 0.86–1.33 1.37b 1.11–1.71 1.35b 1.09–1.69 1.21 0.89–1.63 1.25 0.96–1.62
Inpatient hospitalization in past 12
months (no)
Yes 1.46b 1.13–1.91 1.52b 1.20–1.94 1.32b 1.04–1.68 1.43b 1.13–1.81 1.38b 1.01–1.88 0.85 0.63–1.14
Day patient hospitalization in
past 12 months (no)
Yes 0.86 0.62–1.19 1.13 0.82–1.56 0.97 0.71–1.34 1.20 0.87–1.65 0.80 0.49–1.30 0.80 0.54–1.20
ball the factors in the table are included in the model
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lesser extent. At least one inpatient hospitalization in
past 12 months is also associated with EPP and to a
lesser extent with polypharmacy.
Discussion
In the present study we investigated correlates of (exces-
sive) polypharmacy in a nationwide representative samplein Belgium, taking into account socio-demographic infor-
mation, as well as the health status of the individuals and
the corresponding use of health care.
Excessive polypharmacy was defined here as the use of
nine different medicines or more in the past 24 h, and
not ten medicines or more as suggested in some cases.
The reason for this choice is related to the fact that the
products considered here were limited to official
Table 5 Determinants of polypharmacy - multinomial logistic regression (reference 0–4 medicines; N = 2119), Belgium, 2008
Characteristic 5–8 medicines (N = 617) > = 9 medicines (N = 181)
OR 95 % CI OR 95 % CI
Gender
Males 1 1
Females 1.13 (0.91–1.40) 1.19 (0.83–1.71)
Age
65–69 1 1
70–74 1.30 (0.89–1.92) 1.51 (0.74–3.06)
75–79 1.38 (0.94–2.02) 1.69 (0.86–3.34)
> = 80 1.78a (1.29–2.45) 2.08a (1.15–3.77)
Education
No degree/Primary 1.52a (1.07–2.15) 1.32 (0.75–2.31)
Lower secondary 1.19 (0.83–1.71) 1.17 (0.64–2.13)
Higher secondary 1.18 (0.84–1.67) 1.19 (0.66–2.13)
Higher education 1 1
Equivalent household income in quintiles
1 0.95 (0.63–1.45) 1.62 (0.79–3.31)
2 1.05 (0.70–1.55) 1.31 (0.66–2.60)
3 1.22 (0.82–1.83) 1.41 (0.68–2.90)
4 0.88 (0.56–1.39) 1.20 (0.55–2.62)
5 1 1
Living situation
Living at home 1 1
Living in a residential home for the elderly 1.09 (0.71–1.65) 1.68 (0.92–3.05)
Region
Flemish Region 1 1
Brussels Region 1.06 (0.81–1.39) 1.08 (0.66–1.77)
Walloon Region 1.48a (1.17–1.88) 2.57a (1.71–3.85)
Depression < 12 months
Yes 1.54a (1.02–2.33) 3.48a (2.03–5.97)
No 1 1
Longstanding disease, condition or handicap
Yes 2.45a (1.97–3.05) 5.67a (3.58–8.98)
No 1 1
Contact with GP in past 2 months
Yes 2.92a (2.14–3.98) 4.72a (2.32–9.61)
No 1 1
Ambulatory contact with specialist in past 2 months
Yes 1.19 (0.93–1.51) 1.58a (1.09–2.28)
No 1 1
Inpatient hospitalization in past 12 months
Yes 1.36a (1.05–1.77) 2.20a (1.51–3.20)
No 1 1
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Table 5 Determinants of polypharmacy - multinomial logistic regression (reference 0–4 medicines; N = 2119), Belgium, 2008
(Continued)
Day patient hospitalization in past 12 months
Yes 1.04 (0.74–1.47) 1.07 (0.62–1.86)
No 1 1
adifferences statistically significant
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cines published by the BCPI. The expression “excessive
polypharmacy” (EPP) refers only to the concomitant use
of at least nine different medicines, but has no negative
connotation here in terms of inappropriate polypharmacy.
Indeed, by simply counting the number of different medi-
cines it is not possible to assess the appropriateness of
medicine use. Inappropriate medicine use is far more diffi-
cult to determine and out of the scope of the present
study.
The medicines considered here include all pharmaceut-
ical products used in the past 24 h, either on a regular
basis either occasionally; no information is available on
the indication, the duration of the therapy and the dosage.
EPP can be due to treatment of co-existing diseases or
to the use of different medicines for the same disease.
Polypharmacy is facilitated by the increase in the num-
ber of medicines available on the market and an easier
access to medicines as a result of the exponential growth
of the generic medicine market.
Comparisons between the results from this study and
those from previous studies
Comparisons with other studies are difficult due to dif-
ferent definitions of EPP, countries, study years (more
and more new medicines are produced and made avail-
able), settings (population or institution based), study
design, sampling and data collection methods. The vary-
ing definition of a medicinal product and reference pe-
riods is also a difficulty: some studies, for instance, take
only into account prescription medicines (sometimes
even only the reimbursed ones), while others include
over-the-counter medicines, vitamins and mineral sup-
plements, herbal products; some take only into account
routinely administered medicines, excluding agents only
used when needed (“as-needed”).
Factors related to the health care system can also in-
duce differences between countries: organizational char-
acteristics, availability of medicines on the market,
country specific regulatory medicines measures: pre-
scription status, reimbursement system (subsidized
versus non-subsidized medicines, level of patient co-
payment), prescribing attitudes.
Several medicines may be consumed weekly, monthly
or for short periods. Longer assessment periods tend to
find higher prevalence rates [4]. In 2006 in Sweden [16],the prevalence of five or more different prescription
drugs dispensed was 11.3, 17.2 and 24.4 % when the
study period was 3, 6 and 12 months respectively.
Variations in prevalence rates of EPP between studies
may also be related to differences in the population that
is studied, as it has been shown by Fialová et al. [4]
among older home care patients in Europe, in which dif-
ferences among the eight participating countries were
significant for all study population characteristics.
For all these reasons, the comparison of the results of
the present study with previous studies, was restricted to
studies performed in European countries from 1998
onwards.
In the present study, one fourth of the people aged
65 years or more belongs to the polypharmacy group
and 8.2 % to the EPP-group. In a study of older patients
receiving home care enrolled in metropolitan areas of
eight countries in Europe in 2001–2002 [4], the 7-day
prevalence of medication use was evaluated: excessive
polypharmacy (≥9 medications) was documented in
22.2 % of the patients, varying between 7.0 and 41.2 % of
patients according to the country. In 1998 in the Kuopio
75+ study (Finland), 22.7 % of persons living at home
used ten or more medicines concomitantly [12].
When considering only the people living in a residen-
tial home for the elderly, the mean number of medicines
used per person is 4.5 (range: 0–18) and the prevalence
of EPP is 16.8 %. This figure falls within the range of the
results found in an European study conducted from
2009 to 2011 in nursing homes in eight countries: 8.8–
56.7 % excessive polypharmacy (≥10 medications in the
3 days prior the assessment) [10]. In 2003, Pitruzzella
et al. [6] found in institutions for aged people in the
Walloon Region (Belgium), that 18.6 % of the residents
received more than 10 medicines on one day.
In 2005, a large representative sample of residents
of Belgian nursing homes has been investigated: they
had a mean of 8.4 prescriptions (range: 0–22), one-
third had at least 10 medications lines noted on their
medication chart and only 1 % had no medication
[8]. The higher percentage of EPP in the this last
study could be related to the reference periods used
(medicines taken in the 24 h prior to the interview in
the present study versus “lines on the medication
chart”, which does not mean 24 h use), a selection
bias in the health interview survey (representativity of
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spondents may be in better health) and the fact that
use of medications not frequently used is probably
underestimated in our survey [17].
A multivariate analysis was performed to study the
factors associated with (excessive) polypharmacy. Jyrkkä
et al. also investigated both polypharmacy and excessive
polypharmacy, but polypharmacy was defined as the use
of 6 to 9 drugs concomitantly and excessive polyphar-
macy as the use of 10 or more drugs [12].
Previous studies (see details below) on factors associ-
ated with (excessive) polypharmacy give conflicting re-
sults for gender, age, socio-economic status and living or
not in an institution for elderly people. For depression,
primary care visits and inpatient hospitalization, studies
are in agreement and our results are in line with those
from previous studies.
Female gender is not associated in the present study
with polypharmacy nor EPP. The same was observed in
out-patient prescriptions in 1994 in Sweden [18]. How-
ever two studies showed an association: in the non-
institutionalized elderly in Castile-Leon (Spain) in 2006
[13, 16] and only for excessive polypharmacy in 1998 in
the Kuopio 75+ study (Finland) [12].
Being aged ≥80 years is associated in the present study
with EPP and to a lesser extent to polypharmacy. Some
studies have shown an association only between age
≥85 years and excessive polypharmacy [12], while others
found in nursing homes in Europe (2009–2011) increas-
ing age associated with a reduced rate of excessive poly-
pharmacy [10].
Having no degree or only a primary education degree
is associated in the present study with polypharmacy.
Having an education level lower than higher secondary
is the most associated with the consumption of drugs
acting on the nervous system. Haider et al. [19] observed
in Sweden in 2002 among people aged ≥77 years that
the association between low education level and poly-
pharmacy was not significant (after adjustment for age,
sex, comorbidity, marital status, and living situation).
Living in an institution for the elderly is associated in
the present study with both polypharmacy and EPP, but
the association it is not statistically significant. Haider
et al. [19] observed a higher prevalence of polypharmacy
for older people living in institutions than for the
community-dwelling elderly. In a study of the Belgian
socialist mutuality - Solidaris, the consumption of reim-
bursed medicines was followed in 2009–2011 in patients
aged 70 and over, six months before and six months
after their entry into nursing home. Institutionalization
had no impact on the number of different medicines
used by the older people. On average, patients con-
sumed 8 different molecules and that number was the
same six months before and six months after the entryinto nursing home [20]. In 2011, a study of the Belgian na-
tional union of independent health insurance funds
groups on reimbursed medicines dispensed to their
members residing in nursing homes also showed that
polypharmacy remains virtually unchanged following
institutionalization [21].
Living in the Walloon Region is associated in the
present study with both polypharmacy and excessive
polypharmacy. The multivariate analysis performed on
drug groups at ATC_1 level showed that four of the six
drug groups considered are more consumed in the Wal-
loon Region than in the other Regions of residence. This
could reflect prescription habits and could also be re-
lated to the higher percentage of people in Brussels and
Walloon Regions who reported suffering from at least
one chronic or long-term disease or handicap2.
A self-reported depression during the last year is asso-
ciated in the present study with (excessive) polyphar-
macy. The same was observed in 1998 in the Kuopio 75
+ study [12] as well as in an European study conducted
from 2009 to 2011 in nursing homes [10].
As can be expected, longstanding illness, chronic con-
ditions or handicaps is also associated in the present
study with both polypharmacy and EPP. As this informa-
tion is not mentioned in other studies, we looked at bad
subjective health as a proxy. In the non-institutionalized
older people in Castile-Leõn (Spain) in 2006, regular
poor self-perceived health was associated with polyphar-
macy [13]. In 1997–1999, self-reported poor health cor-
related with increasing number of drugs taken by 70–74
year old community dwelling individuals in Western
Norway [22]. In 1998 in the Kuopio 75+ study, moderate
self-reported health was associated only with excessive
polypharmacy, whereas poor self-reported health was as-
sociated with both polypharmacy and excessive poly-
pharmacy [12]. Also in the 1998–1999 Lieto study,
persons with polypharmacy had poor self-reported
health [23].
At least one contact with a general practitioner in past
two months is associated in the present study with both
polypharmacy and EPP while the contacts with a special-
ist is associated only with EPP. Jörgensen et al. [18]
found in 1994 in Sweden a relationship between the
number of primary care visits and multiple prescription
drug use (5 or more different drugs during one year).
At least one inpatient hospitalization in past
12 months is associated here with both polypharmacy
and EPP, while no relation is found for day patient
hospitalization. Jörgensen et al. [18] found also a rela-
tionship between hospitalization during the year and
multiple prescription drug use.
Medicines active on the cardiovascular system are the
most frequently used drugs, followed by the drugs acting
on the nervous system. This is also the case in the Lieto
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sample of residents of Belgian nursing homes, the drugs
acting on the nervous system were the most frequently
used, followed by those acting on the digestive tract and
on the metabolism, and on the cardiovascular system
[8]. In 2011, a study of the Belgian national union of in-
dependent health insurance funds groups on reimbursed
medicines dispensed to their members residing in nurs-
ing homes found that the drugs acting on the nervous
system were the most frequently used, followed by the
anti-infective agents for systemic use and the cardiovas-
cular medicines [21].
At the ATC_3 level, the most frequently used drugs in
the current study are antithrombotic agents. This has
also been found in Sweden in 2002 [19]. They are
followed by lipid modifying agents (plain), β-blocking
agents, and drugs for peptic ulcer and gastro-oesophageal
reflux disease. In 2012, a study of medicines reimbursed in
Belgium [24] found also the same four most frequently
used drugs associated with polypharmacy. When we con-
sider only people in the polypharmacy or EPP groups, the
same is found in the present study, even if the ranking is
not exactly the same.Strengths and limitations of the present study
This study as some strengths. It is a population-based
study including a representative sample of the general
population living at home and in institutions for the eld-
erly. The information about medicine use, prescribed
and OTC medicines, was based on the respondents self-
reports; the information displayed on their medicine
packages was also checked to “validate” the information.
Topical treatments were included in the medicines con-
sidered because they may also have systemic effects and
consequently increase the risks of interaction [25, 26]
The Health Interview Survey collects information dur-
ing a whole year, allowing to control the seasonal effect
on medicines consumption; it is also allowing to get a
fairly accurate estimate of the number of users of a spe-
cific drug on an average day of the year. Information
was gathered on the use of medicines taken in the 24 h
prior to the interview; the recall bias should consequently
be minimal. In addition, information was collected on
health status and health determinants, which allows to
study factors associated with medicine consumption.
In the present study also non-prescribed and non-
reimbursed medicinal products are included. In pre-
scription database studies, non-prescribed (OTC medi-
cines) and sometimes also non-reimbursed medicines
(medicines not subsidized by the health insurance sys-
tem) are excluded. Such studies allow only to estimate
dispensed medicines, which may differ from the actual
consumption (not all medicines purchased are used andsome medicines can be used a long time after their
purchase).
In 2008 in Belgium, 50 % of out-patient market by
volume are reimbursable medicines, 38 % are non-
reimbursable OTC medicines and 12 % are other non-
reimbursable medicines (generally subject to medical
prescription)3. In the present survey, 18 % of the elderly
population reporting having taken at least one prescrip-
tion medicine over the previous two weeks took also at
least one OTC medicine.
There are also some limitations in the present study.
First, since the use of medicines not listed in the Anno-
tated Directory of Medicines has not been considered -
such as magistral preparations, herbal products, natural
supplements4, homeopathic medicines -, the incidence
of excessive polypharmacy is probably higher than the
one calculated here. Another possible cause of under-
estimation could be related to the fact that some medi-
cines classified as one product may in fact contain more
than one chemical entity; medicine users may thus
wrongly be classified as non-(excessive) polypharmacy
users. The short recall time period used here (24 h) may
also result in an underestimation for the medicines that
are not used daily, but rather weekly or even monthly.
The second limitation is related to the fact that the
health status, the medical diagnosis and the number of
contacts with a health professional are self-reported.
Third, the non-respondents could have a worse health
status and use more medicines than the respondents
[22]. Unfortunately, health related information on the
characteristics of the non-participants, both persons
who were non-contactable and persons who refused to
participate, is lacking. A study however showed that the
presence of at least one household member with a bad
self-perceived health has a negative impact on participa-
tion [27].
In Europe, few population based health surveys in-
clude questions regarding the consumption of all medi-
cines (prescribed and OTC) during the last 24 h; when
they do, they are limited to a city [12], or a county [22].
In France, questions about consumption of medicines
the day before the survey have been included from 1998
till 2010 in the “Enquête sur la Santé et la Protection
Sociale”, but have been removed in 2012 [28]. In 2006 in
Greece, a study excluded individuals reporting only
OTC drug use [29]. In the Lieto study among
community-dwelling persons aged 64 years or over, pre-
scription drugs during 7 days prior to the interview was
recorded [23]. In Barcelona, the use of 13 classes of pre-
scribed and non-prescribed drugs in the two weeks prior
to the interview was registered in a non-institutionalized
population [30]. In the European Health Interview Sur-
vey, which targets the population aged at least 15 and
living in private households, consumption of prescribed
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interview is recorded (but no information is available on
the type of drug). In Spain, consumption by the non-
institutionalized population of prescribed and non-
prescribed drugs in the two weeks prior to the interview
is recorded [13].Conclusions
As older people are a growing population and there is
also an increase in the availability of medicines on the
market, excessive polypharmacy could become an escal-
ating public health problem in the coming years.
In order to optimize drug use, it is necessary to find a
balance between adequate treatment of diseases and
avoiding adverse drug effects. The risks can be mini-
mized by increasing awareness among healthcare profes-
sionals and patients. A periodic review of the patient’s
medicine list that contains all prescribed but also OTC
medicines is necessary to readjust drug treatment and
avoid inappropriate excessive polypharmacy which could
have harmful effects. Physicians have to balance the ben-
efits and risks related to multiple medicine use and to
avoid “prescribing cascades”.
When limiting the number of different medicines
taken, attention should be paid by the physicians to the
danger of under-prescription of beneficial medicines be-
cause the probability of under-prescription increases
with the number of drugs used [31].
The involvement of patients is also an important fac-
tor. As 94 % of persons in the EPP-group had at least
one contact with a GP in past two months, this task of
review and coordination between prescribers is one that
should be fulfilled by GPs. Since more than 90 % of per-
sons in the “(excessive) polypharmacy” group use cardio-
vascular medicines, interventions could be focused on
patients with cardiovascular diseases as suggested in
some studies and mentioned by Jörgensen et al. [18], but
also on other risk groups such as those suffering from
depression and those aged 80 years and over. National
campaigns to raise awareness of prescribers and patients
about the dangers related to excessive polypharmacy
should be organized.
In order to reduce polypharmacy, some countries pub-
lished recommendations, like “a Polypharmacy Guidance
for 2012” by NHS Scotland [32], “Prescribing for older
people” by the Welsh Medicines Resource Centre [33],
or the guidelines published by the Dutch College of
General Practitioners [34]. In Belgium, EBMPracticeNet
(Evidence-Based Medicine) published EBM Guidelines5
in 2010, and the Farmaka association published in 2013
and in 2014 a memento and also newsletters related to
the topic6. This is one of the strategies which could help
to optimize drug therapy, to further develop.The periodical health surveys allow to study the preva-
lence of medicine use and the “true” concomitant expos-
ure to medicines, to study its evolution and the associated
factors. They provide complementary information when
compared to medicine utilization studies based on sales or
prescriptions. The situation must be monitored closely
and studied more in depth in order to identify the most
important determinants of excessive polypharmacy.
Endnotes
1http://www.whocc.no/atc_ddd_index/ World Health
Organization Collaborating Centre. (2009) Use of ATC/
DDD. (Updated 10 December 2009)
2https://hisia.wiv-isp.be/SitePages/Home.aspx
3http://www.pharma.be/assets/files/2178/2178_130361
752513134000.pdf paper downloaded on 14/8/2014
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4CBIP: Only preparations registered as medicinal prepa-
rations are mentioned here. Many preparations made of
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ments. Vitamins are officially considered as food ("nutri-
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